Try

Niagen Bioscience Inc. Common Stock

NAGEUnited States

5 filed reports · 246 financial concepts · 4 earnings calls · 0 media appearances

Filed reports

5 reports · Jun 2025 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR41,212Jun 2025 to Jun 2026
Annual · 10-KSEC EDGAR1710Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Aug 4, 2026425Open
FY2026 Q110-QMar 31, 2026May 6, 2026341Open
FY202510-KDec 31, 2025Mar 4, 2026710Open
FY2025 Q310-QSep 30, 2025Nov 4, 2025302Open
FY2025 Q210-QJun 30, 2025Aug 6, 2025144Open

Financial data

246 concepts · 1,922 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial234 concepts · 1,276 facts · Sep 2022 to Jun 2026

  • Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
  • Restricted cash13 · Dec 2023 to Jun 2026
  • Stockholders equity (US GAAP)13 · Dec 2023 to Jun 2026
  • Advertising expense11 · Jun 2024 to Jun 2026
  • Contract with customer liability revenue recognized11 · Jun 2024 to Jun 2026
  • Cost of revenue (US GAAP)11 · Jun 2024 to Jun 2026
  • General and administrative expense (US GAAP)11 · Jun 2024 to Jun 2026
  • Gross profit (US GAAP)11 · Jun 2024 to Jun 2026
  • Income tax expense benefit11 · Jun 2024 to Jun 2026
  • Interest income expense nonoperating net11 · Jun 2024 to Jun 2026
  • Marketing expense11 · Jun 2024 to Jun 2026
  • Net income loss11 · Jun 2024 to Jun 2026
  • Operating expenses (US GAAP)11 · Jun 2024 to Jun 2026
  • Operating income loss11 · Jun 2024 to Jun 2026
  • Operating lease cost11 · Jun 2024 to Jun 2026
  • Operating lease expense11 · Jun 2024 to Jun 2026
  • Research and development expense11 · Jun 2024 to Jun 2026
  • Revenue11 · Jun 2024 to Jun 2026
  • Selling and marketing expense (US GAAP)11 · Jun 2024 to Jun 2026
  • Selling expense11 · Jun 2024 to Jun 2026
  • Share based compensation11 · Jun 2024 to Jun 2026
  • Short term lease cost11 · Jun 2024 to Jun 2026
  • Stock issued during period value share based compensation11 · Jun 2024 to Jun 2026
  • Stock issued during period value stock options exercised11 · Jun 2024 to Jun 2026

Segment12 concepts · 646 facts · Jun 2024 to Jun 2026

  • Revenue339 · Jun 2024 to Jun 2026
  • Advertising expense33 · Jun 2024 to Jun 2026
  • Cost of revenue (US GAAP)33 · Jun 2024 to Jun 2026
  • General and administrative expense (US GAAP)33 · Jun 2024 to Jun 2026
  • Gross profit (US GAAP)33 · Jun 2024 to Jun 2026
  • Marketing expense33 · Jun 2024 to Jun 2026
  • Operating expenses (US GAAP)33 · Jun 2024 to Jun 2026
  • Operating income loss33 · Jun 2024 to Jun 2026
  • Research and development expense33 · Jun 2024 to Jun 2026
  • Selling expense33 · Jun 2024 to Jun 2026
  • Proceeds from customers6 · Dec 2024 to Dec 2025
  • Gain on settlement of royalty obligation4 · Dec 2025

Segments

646 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments5 members · 342 facts

  • Analytical Reference Standards And Services93 · Jun 2024 to Jun 2026
  • Consumer Products93 · Jun 2024 to Jun 2026
  • Ingredients93 · Jun 2024 to Jun 2026
  • Pharmaceuticals61 · Dec 2024 to Jun 2026
  • Corporate And Reconciling Items2 · Mar 2026 to Jun 2026

Subsegments11 members · 304 facts

  • NIAGEN Related38 · Jun 2024 to Jun 2026
  • Other Goods And Services38 · Jun 2024 to Jun 2026
  • Other Ingredients38 · Jun 2024 to Jun 2026
  • Reference Standards38 · Jun 2024 to Jun 2026
  • TRUNIAGEN Consumer Product38 · Jun 2024 to Jun 2026
  • Consulting And Other33 · Jun 2024 to Mar 2026
  • Food Grade NIAGEN30 · Jun 2024 to Jun 2026
  • Pharmaceutical Grade NIAGEN26 · Sep 2024 to Jun 2026
  • Services And Other9 · Jun 2025 to Jun 2026
  • NIAGEN Ingredient8 · Dec 2024 to Dec 2025
  • Pharmaceutical Grade Niagen8 · Dec 2024 to Dec 2025

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

4 calls · May 2025 to May 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q1May 6, 2026
  • FY2025 Q4Mar 4, 2026
  • FY2025 Q3Nov 4, 2025
  • FY2025 Q1May 10, 2025

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

Niagen Bioscience Inc. Common Stock (NAGE) data · FactIQ